抗血栓药物的血管靶向作用。
Vascular targeting of antithrombotic agents.
机构信息
Department of Pharmacology, University of Pennsylvania, Philadelphia, USA.
出版信息
IUBMB Life. 2011 Aug;63(8):632-9. doi: 10.1002/iub.474. Epub 2011 Jul 15.
Abstract
In this review we discuss the limited efficacy for current pharmacological agents used in prophylaxis and treatment of thrombosis and highlight targeted delivery of anti-thrombotic agents to fibrin, platelets, red blood cells and endothelium.
摘要
在这篇综述中，我们讨论了当前用于预防和治疗血栓形成的药理学药物的疗效有限，并强调了将抗血栓形成药物靶向递送至纤维蛋白、血小板、红细胞和内皮细胞。
相似文献
1
Vascular targeting of antithrombotic agents.抗血栓药物的血管靶向作用。
IUBMB Life. 2011 Aug;63(8):632-9. doi: 10.1002/iub.474. Epub 2011 Jul 15.
2
Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists.
Thromb Haemost. 1995 Jul;74(1):464-72.
3
Clot-Targeted Nanogels for Dual-Delivery of AntithrombinIII and Tissue Plasminogen Activator to Mitigate Disseminated Intravascular Coagulation Complications.用于双重递送抗凝血酶 III 和组织型纤溶酶原激活剂的靶向血栓的纳米凝胶，以减轻弥漫性血管内凝血并发症。
ACS Nano. 2024 Jun 18;18(24):15517-15528. doi: 10.1021/acsnano.4c00162. Epub 2024 Jun 5.
4
Wall passivation for unstable angina.
Semin Interv Cardiol. 1996 Mar;1(1):60-6.
5
Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries.使用抗血栓药物进行局部治疗可减小冠状动脉和外周血栓形成动脉中的血栓大小。
Heart Vessels. 1996;11(3):133-44. doi: 10.1007/BF01745171.
6
Improved microvessel repair: laser welding with an anti-thrombotic solder.
Lasers Surg Med. 2002;31(1):36-40. doi: 10.1002/lsm.10071.
7
[Anticoagulants. Various developmental starting points on direct antithrombins as antithrombotic agents].
Thromb Diath Haemorrh Suppl. 1973;55:179-97.
8
Antithrombotic effect of synthetic thrombin inhibitors.
Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;98(4):483-7.
9
Combination targeting of 'platelets + fibrin' enhances clot anchorage efficiency of nanoparticles for vascular drug delivery.“血小板 + 纤维蛋白”的联合靶向增强了纳米颗粒用于血管药物递送的凝块锚定效率。
Nanoscale. 2020 Nov 7;12(41):21255-21270. doi: 10.1039/d0nr03633a. Epub 2020 Oct 16.
10
Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.针对凝血酶活性、凝血酶受体和凝血酶生成的抗血栓形成策略。
Thromb Haemost. 1997 Jul;78(1):736-41.
引用本文的文献
1
Fibrin-specific poly(N-isopropylacrylamide) nanogels for targeted delivery of tissue-type plasminogen activator to treat thrombotic complications are well tolerated in vivo.用于靶向递送组织型纤溶酶原激活剂以治疗血栓形成并发症的纤维蛋白特异性聚（N-异丙基丙烯酰胺）纳米凝胶在体内具有良好的耐受性。
Bioeng Transl Med. 2021 Dec 11;7(2):e10277. doi: 10.1002/btm2.10277. eCollection 2022 May.
2
Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.基于拉长型植物病毒的纳米颗粒增强溶栓治疗的递释。
Mol Pharm. 2017 Nov 6;14(11):3815-3823. doi: 10.1021/acs.molpharmaceut.7b00559. Epub 2017 Sep 26.
3
Mechanism of Collaborative Enhancement of Binding of Paired Antibodies to Distinct Epitopes of Platelet Endothelial Cell Adhesion Molecule-1.配对抗体与血小板内皮细胞黏附分子-1不同表位结合的协同增强机制
PLoS One. 2017 Jan 13;12(1):e0169537. doi: 10.1371/journal.pone.0169537. eCollection 2017.
4
Advanced drug delivery systems for antithrombotic agents.抗血栓药物的先进药物递送系统。
Blood. 2013 Aug 29;122(9):1565-75. doi: 10.1182/blood-2013-03-453498. Epub 2013 Jun 24.
本文引用的文献
1
Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the newborn pig.红细胞偶联组织型纤溶酶原激活物通过抑制 c-Jun-N 末端激酶和增强 p38 丝裂原活化蛋白激酶预防新生猪脑光血栓形成后脑血管扩张反应受损。
Pediatr Crit Care Med. 2011 Nov;12(6):e369-75. doi: 10.1097/PCC.0b013e3181fe40a7.
2
Targeting antioxidant and antithrombotic biotherapeutics to endothelium.针对血管内皮的抗氧化和抗血栓生物治疗。
Semin Thromb Hemost. 2010 Apr;36(3):332-42. doi: 10.1055/s-0030-1253455. Epub 2010 May 20.
3
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.在血栓形成部位激活的红细胞靶向促尿激酶原酶促物介导的持续抗栓治疗。
Blood. 2010 Jun 24;115(25):5241-8. doi: 10.1182/blood-2010-01-261610. Epub 2010 Apr 21.
4
Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis.靶向循环红细胞的突变型纤溶酶原激活剂用于预防性纤溶。
J Pharmacol Exp Ther. 2010 Mar;332(3):1022-31. doi: 10.1124/jpet.109.159194. Epub 2009 Dec 1.
5
The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator.聚乙二醇化脂质体用于延长组织型纤溶酶原激活剂的循环寿命。
Biomaterials. 2009 Oct;30(29):5751-6. doi: 10.1016/j.biomaterials.2009.07.021. Epub 2009 Aug 4.
6
Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.与载体红细胞结合的可溶性尿激酶受体可结合潜在的纤溶酶原激活剂原，并改变其功能特性。
J Control Release. 2009 Nov 3;139(3):190-6. doi: 10.1016/j.jconrel.2009.07.003. Epub 2009 Jul 16.
7
Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation.红细胞偶联组织型纤溶酶原激活剂通过抑制细胞外信号调节激酶丝裂原活化蛋白激酶（ERK MAPK）的激活，预防小儿脑缺氧/缺血时脑血管舒张反应受损和组织损伤。
J Cereb Blood Flow Metab. 2009 Aug;29(8):1463-74. doi: 10.1038/jcbfm.2009.61. Epub 2009 May 13.
8
Targeted delivery of thrombolytic agents: role of integrin receptors.溶栓剂的靶向递送：整合素受体的作用
Expert Opin Drug Deliv. 2009 May;6(5):499-508. doi: 10.1517/17425240902878002.
9
Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury.红细胞结合型组织纤溶酶原激活剂在实验性创伤性脑损伤中具有神经保护作用。
J Neurotrauma. 2009 Sep;26(9):1585-92. doi: 10.1089/neu.2008.0720.
10
Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator.通过红细胞偶联组织型纤溶酶原激活剂对小鼠进行脑血管血栓预防。
Circulation. 2008 Sep 30;118(14):1442-9. doi: 10.1161/CIRCULATIONAHA.107.750257. Epub 2008 Sep 15.
Zotero 插件